Ranked #3,640 of 8,699 institutional investors
Tri Locum Partners LP
New York, NY
$498M
US stock portfolio at live prices · today −$293K (−0.06%)
Live prices, last trade 10:55 AM ET
- Value at quarter end (Q3 2026)
- $506M
- Change from Q2 2026
- −$307.1M (−37.76%)
- Positions
- 15 · 3 new, 4 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: none$113M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesVRTX 14.0%LLY 13.9%AMRX 9.97%DXCM 7.88%ARGX 5.73%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | 132,896 | $69.8M | 14.0% | Reduced −34% |
| LLY Eli Lilly and Company | 51,015 | $69.3M | 13.9% | Reduced −33% |
| AMRX Amneal Pharmaceuticals, Inc. | 2,326,733 | $49.7M | 9.97% | New |
| DXCM DexCom, Inc. | 489,400 | $39.2M | 7.88% | Reduced −40% |
| ARGX argenx SE | 30,399 | $28.5M | 5.73% | Reduced −27% |
| JNJ Johnson & Johnson | 73,559 | $20.0M | 4.02% | Reduced −83% |
| ELVN Enliven Therapeutics, Inc. | 410,236 | $19.2M | 3.86% | Reduced −53% |
| AXSM Axsome Therapeutics, Inc. | 143,338 | $18.8M | 3.78% | Reduced −35% |
| UTHR United Therapeutics Corporation | 33,000 | $18.3M | 3.67% | Reduced −30% |
| DNTH Dianthus Therapeutics, Inc. | 177,225 | $14.7M | 2.96% | Added +47% |
| MDGL Madrigal Pharmaceuticals, Inc. | 33,668 | $13.1M | 2.64% | Reduced −51% |
| CELC Celcuity Inc. | 202,618 | $11.1M | 2.24% | New |
| RVMD Revolution Medicines, Inc. | 40,019 | $6.6M | 1.33% | Reduced −74% |
| DFTX Definium Therapeutics, Inc. | 144,406 | $4.2M | 0.85% | Reduced −11% |
| VRDN Viridian Therapeutics, Inc. | 90,107 | $2.8M | 0.56% | New |